EGFR/CDK2-IN-2

EGFR/CDK2-IN-2 is a potent dual inhibitor of EGFR (IC50 = 19.6 nM) and CDK2 (IC50 = 87.9 nM) . It demonstrates anticancer activity by inducing apoptosis and S-phase cell cycle arrest in MCF-7 breast cancer cells, with a cellular IC50 of 0.39 μM, making it a useful research tool for oncology and kinase signaling studies.